Navarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the Treatment of Crohn’s Disease (PPAR-Crohn)” (Project Code: 0011-1365-2023-000165), co-funded by the Government of Navarra.

The project’s primary objective was to conduct a Phase 2A clinical trial with MBF-118, a novel investigational compound targeting Crohn’s Disease in its fibrotic stage. Crohn’s Disease is a chronic inflammatory condition of the gastrointestinal tract for which no curative therapies currently exist. Existing treatments, primarily corticosteroids and monoclonal antibodies, focus on controlling inflammation but are administered intravenously and often associated with significant adverse effects.

To date, very few small-molecule therapies are in clinical development specifically aimed at halting or reversing the fibrotic progression of Crohn’s Disease, which represents a critical unmet medical need in advanced stages of the condition.

MBF-118 is a covalent partial agonist of the PPAR-γ receptor currently in clinical development. It has previously demonstrated efficacy in preclinical models of pulmonary fibrosis and ulcerative colitis. The recently completed Phase 2A trial marks a significant milestone, as it is the first trial to demonstrate the excellent safety and tolerability of MBF-118 in patients with Crohn’s Disease. Furthermore, preliminary signals of efficacy were observed, supporting its potential as a “First-in-Class” therapeutic candidate for fibrotic Crohn’s Disease.

This achievement underscores Medibiofarma’s commitment to advancing innovative small-molecule therapies for complex inflammatory and fibrotic diseases. The company continues to pursue cutting-edge research to address areas of high unmet medical need.